Whole brain radiotherapy in patients with NSCLC and brain metastases
نویسندگان
چکیده
1960 www.thelancet.com Vol 388 October 22, 2016 Radiation oncologists are often challenged because of the paucity of randomised trials supporting their clinical practice. In terms of brain metastases treatment, it should be emphasised that there have been fi ve randomised trials assessing whole brain radiotherapy (WBRT): four studies assessing stereotactic radio therapy with or without WBRT for patients with four or less brain metastases, and the present trial by Paula Mulvenna and colleagues in The Lancet assessing optimum supportive care with or without WBRT in a much poorer prognostic population of patients with non-small-cell lung cancer (NSCLC). None of these trials has shown any survival improvement with WBRT, but the fi rst four have shown improved intracranial control with the addition of WBRT. It is only in small-cell lung cancer that prophylactic WBRT improves survival because emergence and development of brain metastases is prevented; but this does not apply to patients with NSCLC Because of advances in the management of NSCLC, the risk of developing brain metastases seems to increase as survival is prolonged. NSCLC management in 2016 still represents a real challenge because detectable brain metastases might be responsible for life-threatening symptoms and serious impairment of quality of life, possibly ameliorated with WBRT. Mulvenna and colleagues are to be congratulated for conducting this non-inferiority phase 3 trial assessing the omission of WBRT in patients with NSCLC and brain metastases. They chose quality-adjusted life-years (QALYs) as the primary outcome measure, and a group of 538 patients between 2007 and 2014 were randomly assigned to receive either WBRT (20 Gy in fi ve daily fractions) and optimal supportive care, including dexamethasone (n=269), or optimal supportive care alone (n=269). The benefi ts in terms of length of life were adjusted to refl ect the quality of life assessed with weekly questionnaires. 536 patients died by October, 2015. The authors concluded that there was no evidence of a diff erence in terms of QALYs, overall survival (hazard ratio [HR] 1·06, 95% CI 0·90–1·26), or quality of life; the median survival from randomisation was less than 3 months. The diff erence between the mean QALYs was 4·7 days (46·4 QALY days for the optimal supportive care plus WBRT group vs 41·7 QALY days for the optimal supportive care only group), with two-sided 90% CI of –12·7 to 3·3. There is no question that this is a large and well designed trial, and that patients were well assessed, with more than 90% of the expected follow-up forms and more than 80% of the quality-of-life forms received. It should be emphasised that owing to poor survival, only 289 (53%, 149 WBRT patients and 140 optimal supportive care patients who were assessed for quality of life at 4 weeks) and 97 (18%, 54 WBRT patients and 43 optimal supportive care patients assessed at 12 weeks) of all enrolled patients answered quality-oflife questionnaires at 4 weeks and 12 weeks, respectively. Should we then consider that there is no place for WBRT Whole brain radiotherapy in patients with NSCLC and brain metastases 3 Hansen ML, Jepsen RM, Olesen JB, et al. Thromboembolic risk in 16 274 atrial fi brillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace 2015; 17: 18–23. 4 Klein AL, Grimm RA, Murray RD, et al, for the Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fi brillation. N Engl J Med 2001; 344: 1411–20. 5 Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fi brillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131. 6 Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes following cardioversion and atrial fi brillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013; 61: 1998–2006. 7 Flaker G, Lopes RD, Al Khatib SM, et al. Effi cacy and safety of apixaban in patients after cardioversion for atrial fi brillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014; 63: 1082–87. 8 Cappato R, Ezekowitz MD, Klein AL, et al, on behalf of the X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fi brillation. Eur Heart J 2014; 35: 3346–55. 9 Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the effi cacy and safety of new oral anticoagulants with warfarin in patients with atrial fi brillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–62. 10 Coleman CM, Khalaf S, Mould S, et al. Novel oral anticoagulants for DC cardioversion procedures: utilization and clinical outcome compared with warfarin. Pacing Clin Electrophysiol 2015; 38: 731–37. 11 Janua ry CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fi brillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 130: 2071–104. 12 Goette A, Merino JL, Ezekowitz M, et al. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fi brillation (ENSURE-AF): a randomized, open-label, phase 3b trial. Lancet 2016; published online Aug 30. http://dx.doi.org/10.1016/ S0140-6736(16)31474-X.
منابع مشابه
Dosimetric comparison of two different whole brain radiotherapy techniques in patients with brain metastases: How to decrease lens dose?
Background: Palliative whole brain radiotherapy (WBRT) has been the standard treatment for brain metastases. Ionizing radiation is known to be one of the most potent cataractogenic agents. We aimed to evaluate two different radiotherapy techniques with respect to the doses received by the organs at risk (OAR) in patients with brain metastasis who undergone WBRT. Materials and Methods: Ten conse...
متن کاملMethods and results of locoregional treatment of brain metastases in patients with non-small cell lung cancer
This article presents methods and results of surgery and radiotherapy of brain metastases from non-small cell lung cancer (BMF-NSCLC). Patients with single BMF-NSCLC, with Karnofsky score ≥ 70 and controlled extracranial disease are the best candidates for surgery. Stereotactic radiosurgery (SRS) is recommended in patients with 1-3 BMF-NSCLC below 3-3.5 cm, with minor neurological symptoms, loc...
متن کاملWhole-brain radiotherapy for NSCLC patients with multiple brain metastases – an update
Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with the majority of patients having advanced disease at presentation. Between 10-20% present with brain metastases (BM) and up to 40% of patients will develop BM. The overall median survival is reported to average three to four months if treated with whole brain radiotherapy (WBRT) alone. Management of BM pat...
متن کاملLDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases
Epidermal growth factor receptor (EGFR) activating mutations are a predictor of tyrosine kinase inhibitor effectiveness in the treatment of non-small-cell lung cancer (NSCLC). The objective of this study is to build a model for predicting the EGFR mutation status of brain metastasis in patients with NSCLC. Observation and model set-up. This study was conducted between January 2003 and December ...
متن کاملGefitinib Alone or with Whole Brain Radiotherapy for Patients with Brain Metastasis from NSCLC
Brain metastases (BM) are found in approximately 20-40% of all patients with non-small-cell lung cancer (NSCLC), especially in adenocarcinoma (Olak 1999; Yawn et al., 2003). The outcomes of BM from NSCLC are very poor with few effective treatment options. The median overall survival time (OS) of patients without treatment is less than 3 months (Nussbaum et al., 1996). Whole brain radiotherapy (...
متن کاملDose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study
BACKGROUND Brain metastases reduce survival because therapeutic options are limited. This phase II study evaluated the efficacy of single-agent therapy with alternating weekly, dose-dense temozolomide in pretreated patients with brain metastases prospectively stratified by primary tumor type. METHODS Eligible patients had bidimensionally measurable brain metastases from histologically/cytolog...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Lancet
دوره 388 شماره
صفحات -
تاریخ انتشار 2016